Fragment-based discovery of potent ERK2 pyrrolopyrazine inhibitors.

导出 LinkOut

翻译打印收藏纠错

第一作者： Daniel J,Burdick

第一单位： Department of Discovery Chemistry, Genentech, Inc., South San Francisco, CA 94080, United States. Electronic address: burdick.dan@gene.com.

作者： Daniel J,Burdick ^[1] ; Shumei,Wang ^[2] ; Christopher,Heise ^[3] ; Borlan,Pan ^[4] ; Jake,Drummond ^[3] ; JianPing,Yin ^[4] ; Lauren,Goeser ^[2] ; Steven,Magnuson ^[2] ; Jeff,Blaney ^[5] ; John,Moffat ^[3] ; Weiru,Wang ^[6] ; Huifen,Chen ^[7]

作者单位： Department of Discovery Chemistry, Genentech, Inc., South San Francisco, CA 94080, United States. Electronic address: burdick.dan@gene.com. ^[1] Department of Discovery Chemistry, Genentech, Inc., South San Francisco, CA 94080, United States. ^[2] Department of Biochemical Pharmacology, Genentech, Inc., South San Francisco, CA 94080, United States. ^[3] Department of Structural Biology, Genentech, Inc., South San Francisco, CA 94080, United States. ^[4] Department of Computational Chemistry, Genentech, Inc., South San Francisco, CA 94080, United States. ^[5] Department of Structural Biology, Genentech, Inc., South San Francisco, CA 94080, United States. Electronic address: wang.weiru@gene.com. ^[6] Department of Computational Chemistry, Genentech, Inc., South San Francisco, CA 94080, United States. Electronic address: chen.huifen@gene.com. ^[7]

关键词 ERK2 Extracellular-regulated kinase Fragment-based Pyrrolopyrazine